Investor Relations Contact:
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule therapeutics derived from its novel boron chemistry platform. We currently have five product candidates in clinical development. Our three lead product candidates include two topically administered dermatologic compounds— tavaborole (formerly AN2690) , an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of psoriasis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria—GSK2251052, or GSK '052 (formerly referred to as AN3365). In addition, we are developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. We have entered into and are seeking partnerships to expand the therapeutic application and commercial value of our boron chemistry platform.
Nov 27, 2013
Anacor Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Nov 12, 2013
Anacor Pharmaceuticals Announces Positive Preliminary Results from AN2728 MUSE Study in Pediatric and Adolescent Patients with Atopic Dermatitis
View all »Events & Presentations
Dec 4, 2013 at 12:00 PM ET
25th Annual Piper Jaffray Healthcare Conference
Nov 12, 2013 at 2:00 PM PT
Anacor Pharmaceuticals, Inc. Conference Call
Nov 7, 2013 at 2:00 PM PT
Anacor Third Quarter 2013 Financial Results Conference Call
Receive Email Alerts
Sign up to receive e-mail alerts
whenever Anacor posts new information to the site.